Last reviewed · How we verify
Q-1802
At a glance
| Generic name | Q-1802 |
|---|---|
| Sponsor | QureBio Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors (PHASE1, PHASE2)
- A Study of Q-1802 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Q-1802 CI brief — competitive landscape report
- Q-1802 updates RSS · CI watch RSS
- QureBio Ltd. portfolio CI